JP2603977B2 - Prevention and treatment of Pasteurella haemolytica infection in livestock - Google Patents

Description

The present invention relates to an agent for preventing and treating Pasteurella haemolytica infection in livestock and a method for preventing and treating the disease.

More specifically, the present invention relates to a prophylactic and therapeutic agent and a method for preventing and treating Pasteurella haemolytica infection in cattle, goats, sheep, and the like containing a crude drug as a main component.

[Prior Art] Livestock Pasteurella haemolytica infection is a disease caused by infection of Pasteurella haemolytica, and is particularly observed in cattle, sheep and goats. Specifically, it mainly causes pneumonia and fever, and also causes mastitis in cows and sepsis in sheep and sheep. Symptoms are similar to parainfluenza caused by parainfluenza virus, and can be mixed with it.

Despite these serious infectious diseases, there are few effective countermeasures, and measures such as appropriate breeding management have been taken, but in many cases they cannot be prevented in practice.

In addition, in order to prevent and treat this disease so far,
For example, it has been practiced to administer antibiotics and other antibacterial agents together with feed. However, in recent years, there is a growing problem that it is not appropriate to administer antibiotics and the like to animals such as livestock due to the occurrence of resistant bacteria and the problem of persistence of antibiotics and the like to animals. Therefore, development of a method for preventing and treating this disease without using antibiotics and the like and development of a prophylactic and therapeutic agent is desired.

[Means for Solving the Problems] The present inventors have conducted studies to solve the above problems, and as a result, have found that certain crude drugs have an effect of suppressing the disease, and completed the present invention. Was.

That is, an object of the present invention is to provide an agent for preventing and treating Pasteurella haemolytica infection in domestic animals and a method for preventing and treating the same.

The present invention relates to mugwort, spinach, red goon, tanzine,
Timo, rhubarb, clover, calyx, squid, hops, lobster, aloe, ubai, emmeiso, gobishi, sanshuyu, sicon, peonies,
One or two selected from the group consisting of Chiuyu and Ephedra
It is an object of the present invention to provide an agent for preventing and treating Pasteurella haemolytica infection in livestock containing at least one kind of crude drug.

The present invention also provides a crude drug in the form of a crude powder, an organic solvent, a mixture of an organic solvent and water or a crude drug extract obtained by extraction with water, or a pasteurella haemolytica infection of the above-mentioned livestock containing a crude drug active ingredient. And a prophylactic and therapeutic agent.

The present invention provides a preventive and therapeutic agent for Pasteurella haemolytica infection in livestock, comprising a crude drug incorporated in feed.

Further, the present invention provides a mugwort, a spinach, a gourd, a tanzine, a timo, a rhubarb, a clover, a calyx, a loquat,
Hops, squid, aloe, squid, squid,
An agent for preventing and treating Pasteurella haemolytica infection in livestock comprising administering an effective amount of one or more crude drugs selected from the group consisting of Gobishi, Sanshuyu, Shikon, Peony, Kinuyu, Chiyu and Ephedra. Is provided.

The present invention also provides a crude drug in the form of a crude drug, an organic solvent, a mixture of an organic solvent and water or a crude drug extract obtained by extraction with water, or a pasteurella hemori of livestock, which is administered in the form of a crude drug active ingredient. It is intended to provide a method for preventing and treating Tica infection.

The present invention also provides a method for preventing and treating Pasteurella haemolytica infection in livestock, which comprises administering a crude drug in a feed.

Artemisia princeps Pampa
nini) or Artemisia montana Pampanin
i) Leaves. It contains about 0.02% of essential oils, the main components of which are cineol, α-thuyon, etc., and also vitamins A, B, C, D and the like. It is used as an astringent and co-blood agent for the treatment of human uterine bleeding and has tonic and blood-supplying effects.

Spinach (Yellow) is spinach (Coptis japonica Ma)
Fine roots are burned off from the roots of kino). It contains berberine, palmatin and the like as components, and is used as a stomach stomach in humans and as an intestinal medicine.

Ogon (golden), Scutellaria baic
alensis Georgi) excluding the cork skin. It contains agonine and baicalin as components and is used as a human anti-inflammatory and antipyretic drug.

Tanjin (Salvia miltiorrhiza)
Bunge). It contains tandinone I, II and cryptotandinone as ingredients and is used for tonicity, menstruation, dysmenorrhea, uterine bleeding, abdominal pain and acne as a human medicine.

Chimo (Chimo) is a sedge (Anemanhena asphodeloid)
es Bunge). It contains saponin, steroid saponin, tannin and the like as components and is used as an anti-inflammatory, antipyretic, antidiarrheal, diuretic, and analgesic in humans.

Rhubarb (Rhuang) is a rhubarb (Rheum palmatum Lin)
ne ') and the roots of closely related plants were almost completely removed and vertically divided. It contains chrysophanol, emodin, emodin monomethyl ether, etc. as anthraquinone derivatives as components, and is used for human gastric stomach bitterness, laxity, and as an anti-inflammatory drug for chronic gastrointestinal diseases, dyspepsia, and constipation. .

The butterfly (Eugenia caryophyll)
ata Thunb.) just before flowering. It contains eugenol, acetyl eugenol, etc. as ingredients, promotes human digestive function, as an anthelmintic, and spices,
It is also used as cosmetics.

Cahi (Cinnamon bark) is Cage (Cinna momum Cassia B)
lume) is obtained by removing the dry skin and branch bark and removing some of the cork layer. It has cinnamaldehyde,
It contains cinnamyl acetate and the like and is used as sweating, antipyretic, analgesic, stomachic, intestinal and anthelmintic in humans.

Loquat (loquat leaf) is loquat (Eriobotrya japonica)
Lindley) leaves are removed as much as possible.
It contains glucose, sucrose, fructose, maltose, and the like as components, and has been used as a cool and stomach medicine for humans and as a preventive drug for hot weather.

Hops are mature ears of hops (Humulus Lupulus Linne '). It has tannin,
Including humulone, lupron, etc., in beer brewing,
Necessary for imparting bitterness and aroma.

The Bayberry (Plum bark) is a bayberry (Myrica rubra S
iebold et Zuccarini). It contains tannin, myricetin, myricitrin and the like as components, is used as astringent in humans for diarrhea, and is effective for bruises.

Aloe is aloe (Aloe arborescens Mill.var.nata
lensis Bergel.) Its components are barbaroin, aloe-emodin, etc., which have been used in the Middle East and Europe for a long time as bitter stomachic or diarrhea.

Ubai (plum), plum (prunus Mume Siebold et Zuc)
The peel is peeled from the immature fruit of crini), buried in medium smoke and dried. Its components are succinic acid, citric acid, malic acid, tartaric acid and the like, and are used as a refreshing astringent for humans, antidiarrheal, exterminating in ascar, antipyretic and the like.

Enmeiso (extended lifegrass) is a cypress (Isodon jap)
onica Hara) or black clover (Isodon trich)
ocarpus Kudo). This is an ingredient
Plectrantin and emmain are used as human stomachic bitters in the treatment of indigestion, anorexia, abdominal pain and the like.

Gobishi is a goal mainly formed on the leaves of nurde (Rhus javanica Linne ') due to a stab wound of a nuldenomifushibashimushi (Melaphis chinensis J. Bell). Including. It is used as a raw material for producing quintuple tincture, tannic acid, gallic acid, and pyrogallol.

Sanshuyu (Cornus offic)
inalis Siebold et Zuccarini). It contains crystalline organic acids, gallic acid, malic acid, tartaric acid, etc. as components and is used as a nourishing, tonic and astringent drug for humans.

Shikon (purple root) is purple (Lithospermum officin)
ale Linne 'var.erythrorhizon Maximowicz). It contains the purple pigment acetyl shikonin as an ingredient and is used as an antipyretic and antidote for humans for the treatment of burns and frostbite.

Peony (peony) is a peony (Paeonia albifl)
ora Pallas var.trichocarpa Bunge). It contains benzoic acid, resin and the like as components and is used as astringent, relieving, analgesic and antispasmodic drugs for humans.

Kinu Oshi (Kanekurako) is a Nani Waibara (Rosa laevi)
gata Michaux). This is an ingredient
Citric acid, malic acid, tannin, saponin, vitamin C
It is used to stop human diarrhea and polyuria.

Chiyu (Jiyu) is a waremokou (Sanguisorba officina)
lis L.) and dried. It contains tannin (17%) and saponin as components, and is used as a hemostatic astringent in humans for hematemesis, hemoptysis, and menorrhagia.

Ephedra (Ephedra) is Ephedra (Ephedra sinica Stapf)
Above ground stem. It contains l-ephedrine, d-pseudoephedrine and the like as components and is used as an antitussive, sweating and diuretic in humans.

As described above, mugwort, spinach used in the present invention,
Japanese gourd, tanjin, chimo, rhubarb, clove, calyx, loquat, hops, lobster, aloe, ubai,
Each of Emmeso, Gobishi, Sanshuyu, Shikon, Peony, Kinuushi, Chiyu and Ephedra has been conventionally used alone or in combination for the prevention and treatment of human diseases. No attempt has been made to use them for the purpose of preventing and treating livestock diseases, especially for preventing and treating infectious diseases in mammals.

The present inventors have conducted various studies focusing on the medicinal effects of the crude drug described above, and as a result, the crude drug described above for the prevention and treatment of Pasteurella haemolytica infection, which is an infectious disease of livestock derived from the bacterium Pasteurella haemolytica. It has been found that it is extremely effective to administer one or more of these in combination, and the present invention has been completed.

That is, as described below, the above-mentioned specific types of crude drugs and their extracts can
Pasteurella haemolytica was found to have a specific bacteriostatic and bactericidal action. And this Past
As a result of the inhibitory effect on eurella haemolytica, Pasteurella haemolyt
It was possible to prevent and cure Pasteurella haemolytica infection, a livestock disease caused by ica.

The fact that the above-mentioned specific crude drugs and extracts were effective for this disease peculiar to domestic animals could not be expected, and this was first revealed by the present inventors.

These crude drugs may be directly administered as raw powder or in the form of an extract or crude drug active ingredient, or they may be added to feed or in the form of a solution, dispersion, semi-solid, powder, granule, or molded product. , Leaching preparations, injection preparations and the like.

The extraction extract is used, for example, by solvent extraction using water, an organic solvent or a mixture of water and an organic solvent, and then directly extracting, concentrating, diluting, or removing the solvent.

As the organic solvent, for example, methanol, ethanol,
n-Propanol, n-butanol, acetone, ethyl acetate, ether, methylene chloride, chloroform, benzene, carbon tetrachloride, petroleum ether and the like are used, and methanol and ethanol are particularly desirable. These organic solvents are 1
It can be used as a species or a mixture of two or more species.

This solvent extraction can be carried out by impregnating or digesting the crude drug into these solvents. 15-25 ° C for cold soaking,
In the case of digestion, it can be performed in a temperature range of 35 to 45 ° C. The extraction time depends on the extraction temperature, but is generally about 5 days or until the soluble components are sufficiently dissolved.

Crude drug active ingredient, for example, the extract extract is further shaken using various solvents, a fraction that is transferred to this solvent is extracted, and the solvent is distilled off, and the effective fraction, that is, the active ingredient may be used as the active ingredient. it can.

Solvents used in this case include non-polar solvents such as lower aliphatic ethers (diethyl ether, ethyl methyl ether, etc.); lower halogen alkanes (chloroform, dichloroethane, dibromoethane, etc.); benzenes (benzene, toluene, Xylene, etc.); and other petroleum solvents (petroleum ether, petroleum benzene, ligroin, etc.).

The remaining aqueous solution obtained by extracting the effective fraction is shake-extracted by using water and a certain organic solvent saturated with water, washed with water, and transferred to an organic solvent layer as a residue. The solvent obtained by distilling off the solvent of the fraction to be used can also be used as an effective fraction, that is, an active ingredient. This effective fraction differs from the above-mentioned effective fraction in the physicochemical properties and the detected components are also different.

The dose is 0.001 mg / kg of body weight in terms of the weight of the crude drug.
/ Day to 100 g / kg body weight / day. This amount is different when used as a prophylactic and therapeutic agent,
Generally, the latter dose will be higher.

The method of administration can be oral or parenteral, and parenteral administration can be intramuscular, intraperitoneal, transdermal, nasal, intravenous, and the like.

[Effects of the Invention] As described above in detail, the present invention provides an effective agent for preventing and treating Pasteurella haemolytica infection in livestock and an effective method for preventing and treating the disease.

Since the prophylactic and therapeutic agent of the present invention is mainly composed of a crude drug or an extract obtained therefrom, there is no problem of the occurrence of resistant bacteria or side effects in the case of antibiotics and the like, and the agent can be administered with confidence.

Further, since there is no concern about the effect of the residual drug on the human body, it is suitable as a drug for preventing and treating Pasteurella haemolytica infection in beef cattle and the like.

Furthermore, the disease can be prevented and treated at a lower cost than in the case where an antibiotic or the like is used.

Hereinafter, the present invention will be described in more detail with reference to Test Examples and Examples.

Test Example 1 The sensitivity of Pasteurella haemolytica to various crude drugs was examined.

Various crude drugs were added to a 50% aqueous ethanol solution 7 times the amount of the crude drug and extracted for 16 hours to obtain an alcohol extract.

The extract was impregnated into an 8 mm-diameter disc by 25 μl and dried. Insert this disc into Pasteurella haemolytica
Was placed on a blood agar medium coated with the strain, and cultured at 37 ° C. for 18 hours, and then the diameter of the inhibition circle was measured.

 Next, Table 1 shows the test results.

Example 1 Basic feed Corn 300 parts by weight Myro 135 〃 Bran 70 〃 Soybean meal 246 小麦 Flour 180 イ エ ロ ー Yellow grease 7 〃 Molasses 30 カ ル シ ウ ム Calcium carbonate 14.5 〃 Calcium tertiary phosphate 11 食 塩 Salt 5 〃 Vitamin and mineral agent 1.5 〃 A test feed was prepared by adding 0.5% by weight of spinach powder to the basic feed. Use this test feed in 30 healthy 50 day old cows.
Heads were fed ad libitum and kept for 90 days. On days 30, 60 and 90 after the start of the test, nasal swabs were collected from cattle,
Lla haemolytica was isolated.

The control was carried out in the same manner as above except that a basal feed was given instead of the test feed.

As a result, in the test plot of the present invention, one pig was separated a total of one time, whereas in the control plot, eight pigs were separated a total of 20 times.

Examples 2 to 21 The same procedure as in Example 1 was carried out except that crude drugs shown in the following table were used instead of water.

 The following table shows the test results.

Example 22 1 kg of each of mugwort, spinach, orange gourd, tanzine, timo, rhubarb, clover, calyx, loquat, hop, yojubayhi, aloe, ubay, emmeiso, gobishi, sanshuyu, shikon, peonies, kinoushi, chiyu, ephedra, Put this in 10 pieces of water at 100 ° C for 1
Time extracted. Each water extract was diluted 1000 times to obtain an extract.

The extract was fed instead of water using 30 healthy 50-day-old cows. As the feed, the same basic feed as that used in Example 1 was used. In the control group, water was given instead of the extract.

In this way, the animals were reared for 90 days, and on days 30, 60, and 90 after the start of the test, intranasal swabs of the cows were collected, and Pasteurella haemolyt
Isolation of ica was performed.

As a result, in all the test plots, the number of bacteria isolated from the control plot and the total number of isolated bacteria were small.

Examples 23 and 24 The procedure of Example 22 was repeated, except that 30 healthy 50-day-old sheep were used instead of cows. As a result, all the test groups were superior to the control group.

──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. ⁶ Identification code Agency reference number FI Technical indication A61K 35/78 AEZ A61K 35/78 AEZQ (56) References JP-A-61-210038 (JP, A JP-A-62-12720 (JP, A) JP-A-48-58115 (JP, A) JP-A-51-61612 (JP, A) JP-A-57-26549 (JP, A) 132847 (JP, A) Kanayoshi Akamatsu, Shinshin Kazoku Yakuhin Dentistry Publishing Co., Ltd., October 15, 1980, 1st edition, 5th printing, 1, 8, 11, 454, 110, 109, 589, 493, 209, 421, 358, 510, 529, 369, 97, 268, 178, 120, 457, 381, 386, 655

Claims (5)

(57) [Claims] Claims: 1. A mugwort, a spinach, a gougon, a tanzine,
Timo, rhubarb, clover, calyx, squid, hops, lobster, aloe, ubai, emmeiso, gobishi, sanshuyu, sicon, peonies,
One or two selected from the group consisting of Chiuyu and Ephedra
An agent for preventing and treating Pasteurella haemolytica infection in livestock containing at least one kind of crude drug. 2. The prophylactic and therapeutic agent according to claim 1, wherein the crude drug is in bulk form. 3. The prophylactic and therapeutic agent according to claim 1, wherein the crude drug is an organic solvent, a mixture of water and an organic solvent or a crude drug extract extracted with water and / or a crude drug active ingredient obtained therefrom. 4. The preventive and therapeutic agent according to claim 1, wherein the crude drug is incorporated in feed. 5. The preventive and therapeutic agent according to claim 1, wherein the livestock is a cow, sheep or goat.